000 00929 a2200265 4500
005 20250513092840.0
264 0 _c19960905
008 199609s 0 0 eng d
022 _a0964-3397
024 7 _a10.1016/s0964-3397(96)81728-9
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMacConnachie, A M
245 0 0 _aClarithromycin (klaricid, Abbott).
_h[electronic resource]
260 _bIntensive & critical care nursing
_cFeb 1996
300 _a60-1 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAnti-Bacterial Agents
_xeconomics
650 0 4 _aClarithromycin
_xeconomics
650 0 4 _aDrug Costs
650 0 4 _aDrug Monitoring
650 0 4 _aHumans
650 0 4 _aRespiratory Tract Infections
_xdrug therapy
773 0 _tIntensive & critical care nursing
_gvol. 12
_gno. 1
_gp. 60-1
856 4 0 _uhttps://doi.org/10.1016/s0964-3397(96)81728-9
_zAvailable from publisher's website
999 _c8693316
_d8693316